drugset / Trial / NCT07719127

Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma

NCT07719127 ↗

Phase 1 Not yet recruiting 20 enrolled Case Comprehensive Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is for participants with glioblastoma. It can cause a tumor immunosuppression which helps myeloid cells that can stop T-cell function. Disulfiram is a drug that has been used in treating other disorders, but this study will examine if disulfiram can help make the tumor environment less immunosuppressive and reduce brain swelling when taken before surgery.

Timeline

Start
2026-10
Primary completion
2027-12-17
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Disulfiram Small molecule 250 mg —
Subject Disulfiram Small molecule 500 mg —

Indications